Metagenomi, Inc. (NASDAQ:MGX) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its position in Metagenomi, Inc. (NASDAQ:MGX) by 344.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 65,753 shares of the company’s stock after purchasing an additional 50,974 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Metagenomi were worth $237,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of MGX. BNP Paribas Financial Markets increased its stake in Metagenomi by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock valued at $28,000 after purchasing an additional 7,256 shares during the period. Virtu Financial LLC acquired a new position in Metagenomi in the 3rd quarter valued at about $33,000. Rhumbline Advisers increased its position in Metagenomi by 123.3% in the 4th quarter. Rhumbline Advisers now owns 11,998 shares of the company’s stock valued at $43,000 after acquiring an additional 6,626 shares during the period. SG Americas Securities LLC purchased a new stake in Metagenomi during the 4th quarter valued at approximately $43,000. Finally, Verition Fund Management LLC acquired a new stake in Metagenomi during the 3rd quarter worth approximately $82,000.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. HC Wainwright lifted their price objective on shares of Metagenomi from $7.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, December 10th. Wells Fargo & Company dropped their price target on shares of Metagenomi from $25.00 to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 18th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Metagenomi has a consensus rating of “Moderate Buy” and a consensus target price of $14.40.

Metagenomi Trading Down 2.9 %

NASDAQ:MGX opened at $1.32 on Wednesday. The company has a market capitalization of $49.35 million and a P/E ratio of -0.50. The firm has a 50-day moving average price of $2.20 and a two-hundred day moving average price of $2.41. Metagenomi, Inc. has a twelve month low of $1.29 and a twelve month high of $10.94.

Metagenomi (NASDAQ:MGX) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). Metagenomi had a negative return on equity of 43.23% and a negative net margin of 134.27%. The business had revenue of $9.61 million for the quarter, compared to analysts’ expectations of $13.18 million. During the same period last year, the business earned ($20.05) earnings per share. On average, equities research analysts predict that Metagenomi, Inc. will post -2.46 earnings per share for the current year.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.